This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Educational Activity

Addressing Barriers to Using Long-Acting Injectable Antipsychotics and Appropriately Monitoring Antipsychotic Adverse Effects

Christoph U. Correll, MD

Published: August 15, 2013

Article Abstract

Conflicting results on the efficacy of long-acting injectable (LAI) antipsychotics in improving adherence and reducing relapse and rehospitalization compared with oral antipsychotic agents have created a barrier to their use in the treatment of schizophrenia. However, clinicians must critically examine these results and interpret them in the context of their study designs. Other barriers to LAI use include clinicians’ lack of familiarity or training and patients’ fear or stigma related to injections. Because nonadherence is common among patients with schizophrenia, LAI antipsychotics are a valuable treatment option to help improve outcomes. Antipsychotic-induced side effects can contribute to both nonadherence and serious physical conditions, so clinicians should regularly monitor patients for metabolic problems, cardiovascular side effects, and extrapyramidal side effects. Improved education and institutional policies can encourage LAI antipsychotic use and consistent health monitoring to help patients reach recovery.

This CME activity is expired. For more CME activities, visit
Find more articles on this and other psychiatry and CNS topics:
The Journal of Clinical Psychiatry
The Primary Care Companion for CNS Disorders


Related Articles

Volume: 74

Quick Links: